Prolong Adjuvant Aromatase Inhibitor Therapy in Breast Cancer?

Cancer Network spoke with Richard Gray, MSc, about the effects of prolonging adjuvant aromatase inhibitor therapy has on breast cancer patients.

Related Content:

San Antonio Breast Cancer Symposium (SABCS)Conference

Pembrolizumab and Etoposide Continue to Demonstrate Clinically Meaningful Survival Benefit in Untreated ES-SCLC

Frontline Tremelimumab/Durvalumab Combo Shows Promising Survival Benefit in Hard-to-Treat Subgroups of mNSCLC

Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLC